Hikma Pharmaceuticals Plc (LON:HIK) has announced an exclusive license deal with Sciecure Pharmaceutical which gives the AIM-quoted group access to a niche injectable anti-viral medicine.
Under the arrangement, Hikma has exclusive right to sell the medicine across the US for a minimum of eight years (with an option for another two-year extension), first it expects to file in early to the US Food and Drug Administration in order to gain approval for the product.
READ: Vectura expects earnings to be materially above forecasts
"We are thrilled to partner with Sciecure, an innovative and vertically integrated company capable of producing high-quality products across the pharmaceutical spectrum from API to finished doses," said Daniel Motto, Hikma executive vice president.
"Our partnership with Sciecure is another example of how Hikma is continuing to expand its pipeline, targeting both niche products and high-volume opportunities, in order to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals."